Related Experiment Video
Updated: Jun 1, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex
Joel M Brittain1, Djane B Duarte, Sarah M Wilson
1Program in Medical Neurosciences, Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Abstract:
The use of N-type voltage-gated calcium channel (CaV2.2) blockers to treat pain is limited by many physiological side effects. Here we report that inflammatory and neuropathic hypersensitivity can be suppressed by inhibiting the binding of collapsin response mediator protein 2 (CRMP-2) to CaV2.2 and thereby reducing channel function. A peptide of CRMP-2 fused to the HIV transactivator of transcription (TAT) protein (TAT-CBD3) decreased neuropeptide release from sensory neurons and excitatory synaptic transmission in dorsal horn neurons, reduced meningeal blood flow, reduced nocifensive behavior induced by formalin injection or corneal capsaicin application and reversed neuropathic hypersensitivity produced by an antiretroviral drug. TAT-CBD3 was mildly anxiolytic without affecting memory retrieval, sensorimotor function or depression. At doses tenfold higher than that required to reduce hypersensitivity in vivo, TAT-CBD3 caused a transient episode of tail kinking and body contortion. By preventing CRMP-2-mediated enhancement of CaV2.2 function, TAT-CBD3 alleviated inflammatory and neuropathic hypersensitivity, an approach that may prove useful in managing chronic pain.
Insights
A novel peptide therapy targeting collapsin response mediator protein 2 (CRMP-2) effectively reduces inflammatory and neuropathic pain by inhibiting calcium channel CaV2.2 function. This approach offers a potential new strategy for managing chronic pain with fewer side effects.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- N-type voltage-gated calcium channel (CaV2.2) blockers are used for pain but cause side effects.
- Collapsin response mediator protein 2 (CRMP-2) enhances CaV2.2 channel function.
Purpose of the Study:
- To investigate if inhibiting CRMP-2 binding to CaV2.2 can suppress inflammatory and neuropathic hypersensitivity.
- To evaluate the therapeutic potential of a CRMP-2 derived peptide (TAT-CBD3) for pain management.
Main Methods:
- A peptide (TAT-CBD3) designed to inhibit CRMP-2 interaction with CaV2.2 was administered.
- Effects on neuropeptide release, synaptic transmission, and nocifensive behaviors were assessed in preclinical models.
- Neuropathic hypersensitivity induced by antiretroviral drugs was evaluated.
Main Results:
- TAT-CBD3 decreased neuropeptide release and synaptic transmission.
- It reduced pain behaviors in formalin and capsaicin tests.
- The peptide reversed established neuropathic hypersensitivity and showed mild anxiolytic effects without cognitive impairment.
- High doses caused transient motor disturbances.
Conclusions:
- Inhibiting CRMP-2 interaction with CaV2.2 is a viable strategy for alleviating inflammatory and neuropathic pain.
- TAT-CBD3 demonstrates potential as a novel analgesic with a distinct mechanism of action.
- This approach may offer an alternative to traditional CaV2.2 blockers for chronic pain management.
Related Concept Videos
Analgesia and Pain Management
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Nociception
Pain
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...